Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | February 27, 2020 | March 03, 2020 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | Director | June 11, 2019 | June 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date February 27, 2020 · Filed March 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.61 · Expires 2030-02-27 | Direct | 24,000 |
Reported balance
After 2020-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-27 · Grant · Acquired 24,000 · Balance 24,000 F1: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021.
Sierra Oncology, Inc.
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2029-06-11 | Direct | 30,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2020 Filed Mar 3, 2020 20:59 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $27.61 | $0.00 |
DisclosureSEC source: 0001567619-20-005544 · doc1.xml · derivative · entry 1 ESTES DANIEL · CIK 0001702527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests and becomes exercisable 100% on the earlier of the date of the next annual meeting of the Issuer's stockholders or February 27, 2021. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 17:48 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001209191-19-036485 · doc4.xml · derivative · entry 1 ESTES DANIEL · CIK 0001702527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:15 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001209191-18-037795 · doc4.xml · derivative · entry 1 ESTES DANIEL · CIK 0001702527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 12, 2018, with 100% of the total shares vested and exercisable on June 12, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 25, 2017 Filed May 30, 2017 16:44 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-17-036145 · doc4.xml · derivative · entry 1 ESTES DANIEL · CIK 0001702527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-05-25 F1 · date: Stock options were granted in connection with the reporting person's appointment to the issuer's board of directors on April 10, 2017. F2 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on June 25, 2017, with 100% of the total shares vested and exercisable on May 25, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.